Several studies have shown that SEs can be sensitive or resistant to BET inhibitors, while rational combinations with oncogenic pathway inhibitors will enhance the therapeutic potential and reduce the side effects of BET inhibitors in CRC [97]. This evidence concerns the gene DNER and colorectal carcinoma.